Dresden

• ANTELOPE – Atezolizumab/Carboplatin/nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in metastatic TTF-1 negative lung adenocarcinoma Ended recruitment
  2023-505054-17-00 6 2023-09-15 metastatic TTF-1 negative lung adenocarcinoma
• A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS) Ended recruitment
  2022-502700-78-00 5 2023-09-01 Alopecia areata (AA)
• A study to test different doses of obrixtamig (BI 764532) combined with ezabenlimab in patients with Small Cell Lung Carcinoma and other neu … Ended recruitment
  2022-502728-30-00 3 2023-08-25 Small Cell Lung Carcinoma expressing DLL3
• LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended recruitment
  2022-501419-15-00 5 2023-08-23 Atrial Fibrillation
• A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended recruitment
  2022-501176-26-00 5 2023-08-04 Acute Ischemic Stroke and High-Risk Transient Ischemic Attack
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended recruitment
  2022-501024-20-00 5 2023-07-25 ER+/HER2- Early Breast Cancer
• A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended recruitment
  2022-501999-26-00 5 2023-07-12 Severe Hypertriglyceridemia (SHTG)
• A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com … Ended recruitment
  2022-501576-25-00 5 2023-07-07 Melanoma
• A Safety, Tolerability, and Efficacy Study of VX-264 in Subjects With Type 1 Diabetes Ended recruitment
  2024-515583-32-00 7 2023-07-06 Type 1 Diabetes Mellitus
• Combined Pembrolizumab and Lenvatinib after definitive Chemoradiation of locally advanced HNSCC in PD-L1 positive patients (CPS≥1) Ended recruitment
  2024-516536-10-00 4 2023-05-25 Locally advanced head and neck squamous cell carcinoma
• OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended recruitment
  2022-501608-85-00 5 2023-05-09 Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
• HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended recruitment
  2022-501939-16-00 5 2023-05-09 Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
• An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma Ended recruitment
  2022-501463-40-01 5 2023-05-03 Locally Advanced or Metastatic Cholangiocarcinoma
• A Phase 3, 24-Week, Randomized, Efficacy and Safety Study with Openlabel Extension of BLU-5937 in Adult Participants with Refractory or Unex … Ended recruitment
  2024-513462-19-00 5 2023-03-30 Refractory Chronic Cough, Including Unexplained Chronic Cough
• A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethas … Ended recruitment
  2023-503444-13-00 5 2023-03-29 Relapsed/refractory multiple myeloma
• A phase 3, randomized, double- blind, study of ianalumab (VAY736) versus placebo in addition to eltrombopag in primary immune thrombocytopen … Ended recruitment
  2024-512890-28-00 5 2023-03-20 Primary immune thrombocytopenia (ITP)
• Phase 2 Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer Ended recruitment
  2023-509583-22-00 4 2023-03-14 Neoplasms, Rectal
• A Phase 2a Study to Evaluate the Safety and Efficacy of MK-5475 in Adults With Pulmonary Hypertension Associated with Chronic Obstructive Pu … Ended recruitment
  2022-501201-13-00 4 2023-03-01 Pulmonary hypertension associated with chronic obstructive pulmonary d
• REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended recruitment
  2023-506924-94-00 5 2023-02-28 Cardiovascular disease
• A MultIceNTER Phase I Peptide VaCcine Trial to Exploit NeoePitope-Specific T Cells for the Treatment of H3-Mutated Gliomas – (INTERCEPT H3) Ended recruitment
  2024-514840-97-00 3 2023-02-15 glioma WHO grade IV (C71.1-9 according to ICD-10 classification)
• Multicenter, prospective, double-blind, randomized, three-armed, placebo-controlled study of long-term therapeutic transfer of encapsulated … Ended recruitment
  2024-517132-22-00 5 2023-01-26 active ulcerative colitis
• An extension study of long-term efficacy, safety and tolerability of remibrutinib in chronic spontaneous urticaria patients who completed pr … Ended recruitment
  2024-510818-33-00 5 2023-01-24 Chronic Spontaneous Urticaria
• A Study of Tirzepatide (LY3298176) on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT- MMO) Ended recruitment
  2022-501744-15-00 5 2023-01-23 Obesity, Overweight
• Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Mult … Ended recruitment
  2022-500861-29-00 5 2023-01-12 Relapsed or Refractory Multiple Myeloma (RRMM)

Showing 577–600 of 943 trials